Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene:: Multicenter validation study

被引:125
作者
van Doorn, LJ
Glupczynski, Y
Kusters, JG
Mégraud, F
Midolo, P
Maggi-Solcà, N
Queiroz, DMM
Nouhan, N
Stet, E
Quint, WGV
机构
[1] Diagnost Lab, NL-2625 AD Delft, Netherlands
[2] Clin Univ UCL Mont Godinne, Yvoir, Belgium
[3] Free Univ Amsterdam, Dept Med Microbiol, Amsterdam, Netherlands
[4] Hop Pellegrin, Bacteriol Lab, F-33076 Bordeaux, France
[5] Monash Med Ctr, Clayton, Vic 3168, Australia
[6] Ist Cantonale Batteriol, Lugano, Switzerland
[7] Univ Fed Minas Gerais, Fac Med, Lab Res Bacteriol, Belo Horizonte, MG, Brazil
关键词
D O I
10.1128/AAC.45.5.1500-1504.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Helicobacter pylori strains from 299 patients were tested in six laboratories in different countries. Macrolide susceptibility of the strains was determined by agar dilution (17.4%) or the epsilometer test (82.6%). Mutations in the 23S ribosomal DNA (rDNA) that are associated with macrolide resistance were analyzed by PCR and reverse hybridization (PCR-line probe assay [LiPA]). This method identifies A2115G, G2141A, A2142G, A2142C, A2142T, A2143G, and A2143C mutations in the 238 rDNA, vacA s-region (s1a, s1b, s1c, and s2) and m-region (m1, m2a, and m2b) genotypes and cagA status were also determined using another PCR-LiPA system. Of the 299 strains investigated by MIC testing, 130 (43.5%) were resistant and 169 (56.5%) were susceptible to clarithromycin, Of the 130 resistant strains, 127 (97.7%) contained 23S rDNA mutations, whereas 167 (98.8%) of the 169 susceptible strains contained wild-type sequences. The predominant mutations were A2143G (45.2%) and A2142G (33.3%). Twenty-eight (19.8%) strains contained multiple 23S rDNA mutations. Only five resistant strains contained the A2142C mutation (three of these in combination with the A2142G mutation), and the A2115G, G2141A, A2142T, and A2143C mutations were not found, MICs of clarithromycin for the A2142G mutant strains were significantly higher than MICs for the A2143G strains. Although there was no significant association between 23S rDNA mutations and the vacA and cagA status, clarithromycin-susceptible strains more often contained mixed vacA genotypes, indicating the presence of multiple H. pylori strains. In conclusion, our data confirmed the very strong association between 238 rDNA mutations and macrolide resistance and showed that the PCR-LiPA permits accurate and reliable diagnosis of macrolide resistance in H. pylori.
引用
收藏
页码:1500 / 1504
页数:5
相关论文
共 30 条
[1]   Ecology of Helicobacter pylori in the human stomach [J].
Blaser, MJ .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (04) :759-762
[2]  
Broutet N, 1998, GUT, V43, pA11
[3]   Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori [J].
Debets-Ossenkopp, YJ ;
Brinkman, AB ;
Kuipers, EJ ;
Vandenbroucke-Grauls, CMJE ;
Kusters, JG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2749-2751
[4]   THE BEST THERAPY FOR HELICOBACTER-PYLORI INFECTION - SHOULD EFFICACY OR SIDE-EFFECT PROFILE DETERMINE OUR CHOICE [J].
DEBOER, WA ;
TYTGAT, GNJ .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1995, 30 (05) :401-407
[5]   Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy -: A meta-analytical approach [J].
Dore, MP ;
Leandro, G ;
Realdi, G ;
Sepulveda, AR ;
Graham, DY .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (01) :68-76
[6]  
DORE MP, 1998, GASTROENTEROLOGY, V114, P1131
[7]   Helicobacter pylori [J].
Dunn, BE ;
Cohen, H ;
Blaser, MJ .
CLINICAL MICROBIOLOGY REVIEWS, 1997, 10 (04) :720-+
[8]   EVALUATION OF THE E-TEST FOR QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING OF HELICOBACTER-PYLORI [J].
GLUPCZYNSKI, Y ;
LABBE, M ;
HANSEN, W ;
CROKAERT, F ;
YOURASSOWSKY, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 1991, 29 (09) :2072-2075
[9]  
Glupczynski Y., 1995, Gut, V37, pA56
[10]  
Houben MHMG, 1999, ALIMENT PHARM THER, V13, P1047